Hepamerz Infusion contains L-Ornithine L-Aspartate (5 gm) as its active ingredient, indicated primarily for the management of hepatic encephalopathy and hyperammonemia associated with chronic liver diseases such as cirrhosis. L-Ornithine L-Aspartate acts by facilitating the detoxification of ammonia through the urea cycle and glutamine synthesis, thereby reducing elevated blood ammonia levels that contribute to neuropsychiatric manifestations in hepatic encephalopathy. Administered intravenously, Hepamerz Infusion provides rapid bioavailability, making it suitable for acute management and stabilization of patients exhibiting symptoms of hepatic encephalopathy. The infusion is typically used as an adjunct to dietary protein management and other supportive measures aimed at improving liver function and neurological status. Clinical studies have demonstrated its efficacy in reducing plasma ammonia concentrations and improving mental status in affected patients. Hepamerz Infusion should be used under medical supervision, with dosage and duration tailored to the severity of the condition and patient response. Caution is advised in patients with hypersensitivity to the components, and monitoring of liver and renal function is recommended during therapy. Overall, Hepamerz Infusion represents a valuable therapeutic option in the comprehensive management of hepatic encephalopathy and related metabolic disturbances.